Bolt Biotherapeutics Inc

NASDAQ:BOLT

1.04

-0.05 (-4.59%)

5:24:31 PM EDT: $1.06 +0.02 (+1.92%)

Market Cap (Intraday)	37.66M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$1.78 Million
Adjusted EPS	-$0.53

See more estimates

10-Day MA	$1.10
50-Day MA	$1.21
200-Day MA	$1.42

See more pivots

Bolt Biotherapeutics Inc Stock, NASDAQ:BOLT

900 Chesapeake Drive, Redwood City, California 94063

United States of America

Phone: +1.650.665.9295

Number of Employees: 94

http://www.boltbio.com

Description

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.